Low Blood Pressure Clinical Trials

Find Low Blood Pressure Clinical Trials Near You

Comparative Analysis Of Dexmedetomidine And Dexamethasone As An Adjuvant To 0.5%Ropivacaine On Onset Of Ultrasound Guided Supraclavicular Brachial Plexus Block In Patients Undergoing Upper Limb Surgeries

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY

To compare the efficacy of dexmedetomidine and dexamethasone as an adjuvant to 0.5%ropivacaine on onset of ultrasound guided supraclavicular brachial plexus block in patients undergoing upper limb surgeries. Ropivacaine hydrochloride, a long acting local anesthetic, is commonly used for supraclavicular block owing to its favorable safety profile especially in terms of minimal cardiotoxicity and less motor block. Dexmedetomidine, a highly selective alpha-2 adrenergic agonist, enhances the quality of supraclavicular block by providing sedation and analgesia while potentially prolonging the duration of block through hyperpolarization of nerve fibers. While, Dexamethasone, a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties, prolongs duration of analgesia by reducing perineural inflammation and inhibiting nociceptive signal transmission. Supraclavicular brachial plexus block offers dense anesthesia for surgical procedures at or distal to the elbow with relatively high success rate, once described as spinal of the arm. Moreover, supraclavicular brachial plexus block is an excellent alternative to general anesthesia in upper limb surgeries.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: t
View:

• Patients scheduled for upper limb surgery below mid-humerus level

• Patients aged 18 to 70 years

• Patients with ASA class I, II and III

Locations
Other Locations
Pakistan
Sahiwal Medical College, Sahiwal
RECRUITING
Sāhīwāl
Contact Information
Primary
Dr Maryam Maqsood, MBBS
maryammaqsood448@gmail.com
00923347036271
Backup
Dr Muhammad Shahid, FCPS
shahidnishtar@gmail.com
00923336173056
Time Frame
Start Date: 2025-01-13
Estimated Completion Date: 2026-03-12
Participants
Target number of participants: 66
Treatments
Other: Group A
0.5%Ropivacaine + 1mcg/kg Dexmedetomidine
Other: Group B
0.5%Ropivacaine + 8mg Dexamethasone
Related Therapeutic Areas
Sponsors
Leads: Sahiwal medical college sahiwal

This content was sourced from clinicaltrials.gov